# Dataset sources

The **drugs** and **cases** in this app are derived from:

1. **Diabetes Canada (2024)** — *Pharmacologic Glycemic Management of Type 2 Diabetes in Adults—2024 Update*. Can J Diabetes 48:415–424.  
   Used for: first-line and intensification recommendations, drug benefits/risks, metformin, SGLT2i, GLP-1 RAs, sulfonylureas, DPP-4 inhibitors, insulin, and teaching points.

2. **Canadian Cardiovascular Society (2022)** — *2022 CCS Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults*. Can J Cardiol 38:1153–1167.  
   Used for: SGLT2i in HF and CKD, GLP-1 RA for ASCVD and stroke, screening (eGFR, UACR, A1c, LVEF), and evidence quotes.

Additional PDFs referenced (content integrated where applicable):  
- dc26s016.pdf, dc26s009.pdf  
- *Pharmacologic Glycemic Management of Type 2 Diabetes in Adults—2024 Update* (full text)  
- PIIS0828282X2200335X.pdf  
- A13_dci220034.pdf  

Tags used in cases and drugs (e.g. `ckd`, `hf`, `ascvd`, `cost_sensitive`, `high_hypoglycemia_risk`, `weight_loss_goal`, `gi_intolerance`) align with these guidelines for scoring and feedback.
